Induced Urinary Crystal Formation As an Analytical Strategy for the Prediction and Monitoring of Urolithiasis and Other Metabolism-related Disorders

Overview

Journal EPMA J

Date 2014 Sep 11

PMID 25206937

Citations 2

Authors

Norbert Laube

Wolfgang Berg

Falk Bernsmann

Sascha Gravius

Florian Klein

Stefan Latz

Dirk von Mallek

Tadeusz Porowski

Thomas Randau

Anna Wasilewska

Christian Fisang

Affiliations

Soon will be listed here.

Abstract

Crystal formation reflects the entire composition of the surrounding solution. In case of urolithiasis, induced crystal formation in native urine has led to the development of the Bonn-Risk-Index (BRI), a valuable tool to quantify an individual's risk of calcium oxalate urolithiasis. If the progression of a disease is associated with characteristic changes in the activities of urinary components, this leads to an altered urinary crystallisation capacity. Therefore, the results of induced urinary crystal formation can be used to detect and monitor any disease linked to the altered urinary composition. Since crystal formation inherently takes into account the entire urinary composition, the influence of the disease on individual urinary parameters does not have to be known in order to monitor the consequent pathologic alterations. In this paper, we review the background of urinary crystal formation analysis and describe its established application in urolithiasis monitoring as well as potential further fields of clinical application.

Citing Articles

Kinetics of calcium oxalate crystal formation in urine.

Laube N, Klein F, Bernsmann F Urolithiasis. 2016; 45(2):151-157.

PMID: 27328814 DOI: 10.1007/s00240-016-0900-y.

Urolithiasis--an interdisciplinary diagnostic, therapeutic and secondary preventive challenge.

Fisang C, Anding R, Muller S, Latz S, Laube N Dtsch Arztebl Int. 2015; 112(6):83-91.

PMID: 25721435 PMC: 4349965. DOI: 10.3238/arztebl.2015.0083.

References

Mitome J, Kawaguchi Y, Arase S, Horino T, Okada H, Osaka N . A case of renal sarcoidosis: a special reference to calcium metabolism as a diagnostic and the therapeutic implications. Clin Exp Nephrol. 2004; 8(4):375-9. DOI: 10.1007/s10157-004-0323-x. View

Chung S, Liu S, Lin H . A population-based study on the association between urinary calculi and kidney cancer. Can Urol Assoc J. 2013; 7(11-12):E716-21. PMC: 3840508. DOI: 10.5489/cuaj.366. View

Tiselius H . An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease. Clin Chim Acta. 1982; 122(3):409-18. DOI: 10.1016/0009-8981(82)90145-0. View

Grases F, Millan A, Sohnel O . Role of agglomeration in calcium oxalate monohydrate urolith development. Nephron. 1992; 61(2):145-50. DOI: 10.1159/000186862. View

Hess B . The role of Tamm-Horsfall glycoprotein and Nephrocalcin in calcium oxalate monohydrate crystallization processes. Scanning Microsc. 1991; 5(3):689-95; discussion 696. View

Mocan H, Yildiran A, Camlibel T, Kuzey G . Microscopic nephrocalcinosis and hypercalciuria in nephrotic syndrome. Hum Pathol. 2000; 31(11):1363-7. View

Chien Y, Masica D, Gray J, Nguyen S, Vali H, McKee M . Modulation of calcium oxalate dihydrate growth by selective crystal-face binding of phosphorylated osteopontin and polyaspartate peptide showing occlusion by sectoral (compositional) zoning. J Biol Chem. 2009; 284(35):23491-501. PMC: 2749123. DOI: 10.1074/jbc.M109.021899. View

Szeto C, Chow K . Nephrotoxicity related to new therapeutic compounds. Ren Fail. 2005; 27(3):329-33. View

Verma N, Yadav G, Dhawan N, Kumar A . Squamous cell carcinoma of kidney co-existing with renal calculi: a rare tumour. BMJ Case Rep. 2012; 2011. PMC: 3063286. DOI: 10.1136/bcr.10.2010.3388. View

10.

Rodgers A, Allie-Hamdulay S, Jackson G . Therapeutic action of citrate in urolithiasis explained by chemical speciation: increase in pH is the determinant factor. Nephrol Dial Transplant. 2005; 21(2):361-9. DOI: 10.1093/ndt/gfi211. View

11.

Gawade P, Ness K, Sharma S, Li Z, Srivastava D, Spunt S . Association of bone mineral density with incidental renal stone in long-term survivors of childhood acute lymphoblastic leukemia. J Cancer Surviv. 2012; 6(4):388-97. PMC: 3529472. DOI: 10.1007/s11764-012-0241-y. View

12.

Davidson M, Thakkar S, Hix J, Bhandarkar N, Wong A, Schreiber M . Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004; 116(8):546-54. DOI: 10.1016/j.amjmed.2003.09.045. View

13.

Perazella M . Crystal-induced acute renal failure. Am J Med. 1999; 106(4):459-65. DOI: 10.1016/s0002-9343(99)00041-8. View

14.

Sorensen S, Hansen K, Bak S, Justesen S . An unidentified macromolecular inhibitory constituent of calcium oxalate crystal growth in human urine. Urol Res. 1990; 18(6):373-9. DOI: 10.1007/BF00297368. View

15.

KLAHR S, SCHREINER G, Ichikawa I . The progression of renal disease. N Engl J Med. 1988; 318(25):1657-66. DOI: 10.1056/NEJM198806233182505. View

16.

Laube N, Klein F, Bernsmann F, Fisang C . [New diagnostic tool for individual monitoring of urolithiasis risk and other metabolic diseases]. Dtsch Med Wochenschr. 2014; 139(34-35):1721-5. DOI: 10.1055/s-0034-1370196. View

17.

Praga M, Martinez M, Andres A, Alegre R, Vara J, Morales E . Association of thin basement membrane nephropathy with hypercalciuria, hyperuricosuria and nephrolithiasis. Kidney Int. 1998; 54(3):915-20. DOI: 10.1046/j.1523-1755.1998.00065.x. View

18.

May P, Muray K . Jess, a joint expert speciation system-II. The thermodynamic database. Talanta. 1991; 38(12):1419-26. DOI: 10.1016/0039-9140(91)80290-g. View

19.

Daudon M, Jungers P . Drug-induced renal calculi: epidemiology, prevention and management. Drugs. 2004; 64(3):245-75. DOI: 10.2165/00003495-200464030-00003. View

20.

Christensen B, Petersen T, Sorensen E . Post-translational modification and proteolytic processing of urinary osteopontin. Biochem J. 2007; 411(1):53-61. DOI: 10.1042/BJ20071021. View